Status:
COMPLETED
Reorganization of the Healthcare System During COVID-19 Pandemic: Impact on Management of Patients With Exocrine Pancreatic Cancer
Lead Sponsor:
CHU de Reims
Conditions:
Pancreatic Adenocarcinoma
Eligibility:
All Genders
18+ years
Brief Summary
Pancreatic adenocarcinoma will be the 2nd cause of death by cancer in Europe in 2030. Pancreatic adenocarcinoma has poor prognosis with an all-stages combined 5-year survival rate below 8%. Since Dec...
Detailed Description
The aim of this study is to study impact of reorganization of the healthcare system during COVID-19 pandemic on pancreatic adenocarcinoma patients management
Eligibility Criteria
Inclusion
- Inclusion criteria :
- aged 18 or over,
- with pancreatic adenocarcinoma diagnosed by anatomopathological specimen or without biopsy but with suspicion of pancreatic adenocarcinoma in presence of imaging techniques or Ca19.9 level without evidence for neuroendocrine tumor,
- assessed during multidisciplinary meeting in one participating center between 01/09/2019 and 31/10/2020,
- accepting to participate to the study,
- with or without SARS-CoV-2 infection.
- Exclusion criteria :
- with neuroendocrine neoplasia
- for whom histology showed non pancreatic
- with cystadenoma or IPMN without invasive adenocarcinoma
Exclusion
Key Trial Info
Start Date :
April 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 31 2022
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT04406571
Start Date
April 1 2020
End Date
May 31 2022
Last Update
January 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Damien JOLLY
Reims, France